Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Manuscript
  • Published:

Internalization and cell cycle-dependent killing of leukemic cells by Gemtuzumab Ozogamicin: rationale for efficacy in CD33-negative malignancies with endocytic capacity

Leukemia volume 18, pages 316–325 (2004)Cite this article

Abstract

Multicenter phase II trials with Gemtuzumab Ozogamicin (GO/Mylotarg®), consisting of a CD33 antibody linked to the cytotoxic drug calicheamicin, have shown a 30% overall response rate in relapsed acute myeloid leukemia patients. However, no clear correlation was observed between CD33 expression on leukemic blasts and response to GO therapy. We analyzed the CD33 specificity of GO-induced cell death and the effect of GO on CD33-negative malignancies. We demonstrate that lysis induced by clinically relevant GO concentrations is partially CD33 mediated, and that efficient non-CD33-mediated GO uptake can occur via endocytosis. In agreement with these results, we observed GO-mediated death of human CD33-negative acute lymphoblastic leukemia cells both in vitro and in vivo in an NOD/SCID mouse model. Finally, sensitivity to GO-induced cell death was at least partially determined by the activation status of leukemic cells, with cells in activated phases of the cell cycle being most effective in both CD33-specific GO internalization, renewed expression of CD33 molecules, and non-CD33-mediated GO uptake via endocytosis. In conclusion, these data provide mechanistic insight into the efficacy of GO in CD33-positive as well as in CD33-negative malignancies with endocytic capacity, and provide a rationale for the use of GO in the treatment of malignancies with endocytic capacity.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7
Figure 8

Similar content being viewed by others

References

  1. Zittoun RA, Mandelli F, Willemze R, de Witte T, Labar B, Resegotti L et al. Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) Leukemia Cooperative Groups. N Engl J Med 1995; 332: 217–223.

    Article  CAS  PubMed  Google Scholar 

  2. Lowenberg B, Downing JR, Burnett A . Acute myeloid leukemia. N Engl J Med 1999; 341: 1051–1062.

    Article  CAS  PubMed  Google Scholar 

  3. Appelbaum FR . Antibody-targeted therapy for myeloid leukemia. Semin Hematol 1999; 36: 2–8.

    CAS  PubMed  Google Scholar 

  4. Sievers EL . Clinical studies of new ‘biologic’ approaches to therapy of acute myeloid leukemia with monoclonal antibodies and immunoconjugates. Curr Opin Oncol 2000; 12: 30–35.

    Article  CAS  PubMed  Google Scholar 

  5. Bernstein ID . Monoclonal antibodies to the myeloid stem cells: therapeutic implications of CMA-676, a humanized anti-CD33 antibody calicheamicin conjugate. Leukemia 2000; 14: 474–475.

    Article  CAS  PubMed  Google Scholar 

  6. Freeman SD, Kelm S, Barber EK, Crocker PR . Characterization of CD33 as a new member of the sialoadhesin family of cellular interaction molecules. Blood 1995; 85: 2005–2012.

    CAS  PubMed  Google Scholar 

  7. Dinndorf PA, Andrews RG, Benjamin D, Ridgway D, Wolff L, Bernstein ID . Expression of normal myeloid-associated antigens by acute leukemia cells. Blood 1986; 67: 1048–1053.

    CAS  PubMed  Google Scholar 

  8. Griffin JD, Linch D, Sabbath K, Larcom P, Schlossman SF . A monoclonal antibody reactive with normal and leukemic human myeloid progenitor cells. Leukemia Res 1984; 8: 521–534.

    Article  CAS  Google Scholar 

  9. Wagner JE, Collins D, Fuller S, Schain LR, Berson AE, Almici C et al. Isolation of small, primitive human hematopoietic stem cells: distribution of cell surface cytokine receptors and growth in SCID-Hu mice. Blood 1995; 86: 512–523.

    CAS  PubMed  Google Scholar 

  10. Andrews RG, Singer JW, Bernstein ID . Precursors of colony-forming cells in humans can be distinguished from colony-forming cells by expression of the CD33 and CD34 antigens and light scatter properties. J Exp Med 1989; 169: 1721–1731.

    Article  CAS  PubMed  Google Scholar 

  11. McGavin JK, Spencer CM . Gemtuzumab ozogamicin. Drugs 2001; 61: 1317–1322.

    Article  CAS  PubMed  Google Scholar 

  12. Hamann PR, Hinman LM, Hollander I, Beyer CF, Lindh D, Holcomb R et al. Gemtuzumab ozogamicin, a potent and selective anti-CD33 antibody- calicheamicin conjugate for treatment of acute myeloid leukemia. Bioconjugate Chem 2002; 13: 47–58.

    Article  CAS  Google Scholar 

  13. van der Velden V, te Marvelde JG, Hoogeveen PG, Bernstein ID, Houtsmuller AB, Berger MS et al. Targeting of the CD33-calicheamicin immunoconjugate Mylotarg (CMA-676) in acute myeloid leukemia: in vivo and in vitro saturation and internalization by leukemic and normal myeloid cells. Blood 2001; 97: 3197–3204.

    Article  CAS  PubMed  Google Scholar 

  14. Zein N, Sinha AM, McGahren WJ, Ellestad GA . Calicheamicin gamma 1I: an antitumor antibiotic that cleaves double- stranded DNA site specifically. Science 1988; 240: 1198–1201.

    Article  CAS  PubMed  Google Scholar 

  15. Nicolaou KC, Smith AL, Yue EW . Chemistry and biology of natural and designed enediynes. Proc Natl Acad Sci USA 1993; 90: 5881–5888.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Sievers EL, Larson RA, Stadtmauer EA, Estey E, Lowenberg B, Dombret H et al. Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. J Clin Oncol 2001; 19: 3244–3254.

    Article  CAS  PubMed  Google Scholar 

  17. Larson RA, Boogaerts M, Estey E, Karanes C, Stadtmauer EA, Sievers EL et al. Antibody-targeted chemotherapy of older patients with acute myeloid leukemia in first relapse using Mylotarg (gemtuzumab ozogamicin). Leukemia 2002; 16: 1627–1636.

    Article  CAS  PubMed  Google Scholar 

  18. Jilani I, Estey E, Huh Y, Joe Y, Manshouri T, Yared M et al. Differences in CD33 intensity between various myeloid neoplasms. Am J Clin Pathol 2002; 118: 560–566.

    Article  PubMed  Google Scholar 

  19. Rajvanshi P, Shulman HM, Sievers EL, McDonald GB . Hepatic sinusoidal obstruction after gemtuzumab ozogamicin (Mylotarg) therapy. Blood 2002; 99: 2310–2314.

    Article  CAS  PubMed  Google Scholar 

  20. Leopold LH, Berger MS, Feingold J . Acute and long-term toxicities associated with gemtuzumab ozogamicin (mylotarg(r)) therapy of acute myeloid leukemia. Clin Lymphoma 2002; 2 (Suppl 1): S29–S34.

    Article  PubMed  Google Scholar 

  21. Jedema I, Barge RMY, Nijmeijer BA, Willemze R, Falkenburg JHF . Recruitment of leukemic cells from G0 phase of the cell cycle by interferons results in conversion of resistance to daunorubicin. Leukemia 2003; 17: 2049–2051.

    Article  CAS  PubMed  Google Scholar 

  22. Nijmeijer BA, Mollevanger P, Zelderen-Bhola SL, Kluin-Nelemans HC, Willemze R, Falkenburg JH . Monitoring of engraftment and progression of acute lymphoblastic leukemia in individual NOD/SCID mice. Exp Hematol 2001; 29: 322–329.

    Article  CAS  PubMed  Google Scholar 

  23. Lange B, Valtieri M, Santoli D, Caracciolo D, Mavilio F, Gemperlein I et al. Growth factor requirements of childhood acute leukemia: establishment of GM-CSF-dependent cell lines. Blood 1987; 70: 192–199.

    CAS  PubMed  Google Scholar 

  24. Jedema I, Barge RM, Willemze R, Falkenburg JH . High susceptibility of human leukemic cells to Fas-induced apoptosis is restricted to G(1) phase of the cell cycle and can be increased by interferon treatment. Leukemia 2003; 17: 576–584.

    Article  CAS  PubMed  Google Scholar 

  25. Duperrier K, Eljaafari A, Dezutter-Dambuyant C, Bardin C, Jacquet C, Yoneda K et al. Distinct subsets of dendritic cells resembling dermal DCs can be generated in vitro from monocytes, in the presence of different serum supplements. J Immunol Methods 2000; 238: 119–131.

    Article  CAS  PubMed  Google Scholar 

  26. Dowell JA, Korth-Bradley J, Liu H, King SP, Berger MS . Pharmacokinetics of gemtuzumab ozogamicin, an antibody-targeted chemotherapy agent for the treatment of patients with acute myeloid leukemia in first relapse. J Clin Pharmacol 2001; 41: 1206–1214.

    Article  CAS  PubMed  Google Scholar 

  27. Jordan CT, Yamasaki G, Minamoto D . High-resolution cell cycle analysis of defined phenotypic subsets within primitive human hematopoietic cell populations. Exp Hematol 1996; 24: 1347–1355.

    CAS  PubMed  Google Scholar 

  28. van Oijen MG, Medema RH, Slootweg PJ, Rijksen G . Positivity of the proliferation marker Ki-67 in noncycling cells. Am J Clin Pathol 1998; 110: 24–31.

    Article  CAS  PubMed  Google Scholar 

  29. Danova M, Riccardi A, Mazzini G . Cell cycle-related proteins and flow cytometry. Haematologica 1990; 75: 252–264.

    CAS  PubMed  Google Scholar 

  30. Landberg G, Tan EM, Roos G . Flow cytometric multiparameter analysis of proliferating cell nuclear antigen/cyclin and Ki-67 antigen: a new view of the cell cycle. Exp Cell Res 1990; 187: 111–118.

    Article  CAS  PubMed  Google Scholar 

  31. Schwarting R, Gerdes J, Niehus J, Jaeschke L, Stein H . Determination of the growth fraction in cell suspensions by flow cytometry using the monoclonal antibody Ki-67. J Immunol Methods 1986; 90: 65–70.

    Article  CAS  PubMed  Google Scholar 

  32. Naito K, Takeshita A, Shigeno K, Nakamura S, Fujisawa S, Shinjo K et al. Calicheamicin-conjugated humanized anti-CD33 monoclonal antibody (gemtuzumab zogamicin, CMA-676) shows cytocidal effect on CD33-positive leukemia cell lines, but is inactive on P-glycoprotein-expressing sublines. Leukemia 2000; 14: 1436–1443.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Hematology, Laboratory of Experimental Hematology, Leiden University Medical Center, The Netherlands

    I Jedema, R M Y Barge, B A Nijmeijer, R Willemze & J H F Falkenburg

  2. Department of Immunology, Erasmus MC, University Medical Center Rotterdam, The Netherlands

    V H J van der Velden & J J M van Dongen

Authors
  1. I Jedema
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. R M Y Barge
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. V H J van der Velden
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. B A Nijmeijer
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. J J M van Dongen
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. R Willemze
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. J H F Falkenburg
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to I Jedema.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Jedema, I., Barge, R., van der Velden, V. et al. Internalization and cell cycle-dependent killing of leukemic cells by Gemtuzumab Ozogamicin: rationale for efficacy in CD33-negative malignancies with endocytic capacity. Leukemia 18, 316–325 (2004). https://doi.org/10.1038/sj.leu.2403205

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.leu.2403205

Keywords

This article is cited by

Search

Advanced search

Quick links